EP 2679237 A1 20140101 - Myostatin inhibition for enhancing muscle and/or improving muscle function

Title (en)

Myostatin inhibition for enhancing muscle and/or improving muscle function

Title (de)

Myostatinhemmung zur Verstärkung und/oder Verbesserung der Muskelfunktion

Title (fr)

Inhibition de la myostatine destinée à améliorer le muscle et/ou la fonction musculaire

Publication

EP 2679237 A1 20140101 (EN)

Application

EP 13177677 A 20071129

Priority

US 86160206 P 20061129
EP 07864918 A 20071129

Abstract (en)

The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin. Examples of genes to be delivered are genes encoding proteins such as Follistatin, Follistatin-related gene-1 (FLRG-I), growth differentiation factor associated protein- 1 (GASP-I) and myostatin precursor propeptide. The genes can be delivered using, for example, a recombinant Adeno-associated virus (rAAV), lentivirus or equine-associated virus capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods of the invention expression of proteins such as activin lib and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock.

IPC 8 full level

A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 48/00 (2006.01); A61P 21/00 (2006.01); C12N 15/861 (2006.01)

CPC (source: EP US)

A61K 9/0019 (2013.01 - US); A61K 35/761 (2013.01 - US); A61K 38/18 (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); A61P 21/00 (2017.12 - EP); C07K 14/4703 (2013.01 - EP US); C12N 7/00 (2013.01 - US); C12N 15/86 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); C12N 2750/14142 (2013.01 - US); C12N 2750/14143 (2013.01 - EP US); C12N 2799/025 (2013.01 - EP US)

Citation (applicant)

US 5041538 A 19910820 - LING NICHOLAS C K [US], et al
US 5942420 A 19990824 - HOLTZMAN DOUGLAS A [US]
US 6410232 B1 20020625 - HOLTZMAN DOUGLAS A [US]
US 6537966 B1 20030325 - DUAN D ROXANNE [US], et al
US 6953662 B2 20051011 - DUAN D ROXANNE [US], et al
WO 0183692 A2 20011108 - UNIV PENNSYLVANIA [US], et al
US 5173414 A 19921222 - LEBKOWSKI JANE S [US], et al
WO 9513365 A1 19950518 - TARGETED GENETICS CORP [US], et al
US 5658776 A 19970819 - FLOTTE TERENCE R [US], et al
WO 9513392 A1 19950518 - OHIO MED COLLEGE [US], et al
WO 9617947 A1 19960613 - TARGETED GENETICS CORP [US], et al
WO 9709441 A2 19970313 - GENZYME CORP [US], et al
WO 9708298 A1 19970306 - GENZYME CORP [US], et al
WO 9721825 A1 19970619 - SYSTEMIX INC [US], et al
WO 9706243 A1 19970220 - PASTEUR MERIEUX SERUMS VACC [FR], et al
WO 9911764 A2 19990311 - TARGETED GENETICS CORP [US], et al
US 5786211 A 19980728 - JOHNSON PHILIP R [US]
US 5871982 A 19990216 - WILSON JAMES M [US], et al
US 6258595 B1 20010710 - GAO GUANG-PING [US], et al
US 6566118 B1 20030520 - ATKINSON EDWARD M [US], et al
WO 9809657 A2 19980312 - UNIV PENNSYLVANIA [US], et al
WO 02053703 A2 20020711 - CHILDRENS HOSPITAL INC [US]
LEE, ANN REV CELL DEV BIOL, vol. 20, 2004, pages 61 - 86
GROBET ET AL., NAT GENET, vol. 17, 1997, pages 71 - 74
KAMBADUR ET AL., GENOME RES, vol. 7, 1997, pages 910 - 915
MCPHERRON; LEE, PROC NATL ACAD SCI USA, vol. 94, 1997, pages 12457 - 12461
SCHUELKE ET AL., N ENG J MED, vol. 350, 2004, pages 2682 - 2688
ZIMMERS ET AL., SCIENCE, vol. 296, no. 5572, 2002, pages 1486 - 1488
WAGNER ET AL., ANN NEUROL, vol. 52, 2002, pages 832 - 836
BOGDANOVICH ET AL., NATURE, vol. 420, 2002, pages 418 - 421
WHITTEMORE ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 300, 2003, pages 965 - 971
TOBIN; CELESTE, CURR OPIN PHARMA, vol. 5, 2005, pages 328 - 332
WAGNER, CURR OPIN RHEUMATOL, vol. 17, 2005, pages 720 - 724
WOLFMAN ET AL., PROC NATL ACAD SCI US, vol. 100, 2003, pages 15842 - 15846
BOGDANOVICH ET AL., FASEB J, vol. 19, 2004, pages 543 - 549
LEE; MCPHERRON, PROC NATL ACAD SCI USA, vol. 98, no. 16, 2001, pages 9306 - 9311
AMTHOR ET AL., DEVELOPMENTAL BIOL., vol. 270, 2004, pages 19 - 30
HILL ET AL., JBIOL CHEM, vol. 277, no. 43, pages 40735 - 40741
LEE, ANNU REV CELL DEV L3IOL., vol. 20, pages 61 - 86
SRIVASTAVA ET AL., J VIROL, vol. 45, 1983, pages 555 - 564
RUFFING ET AL., J GEN VIROL, vol. 75, 1994, pages 3385 - 3392
MUZYCZKA, CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 158, 1992, pages 97 - 129
CLARK ET AL., HUM GENE THER, vol. 8, 1997, pages 659 - 669
KESSLER ET AL., PROC NAT. ACAD SC. USA, vol. 93, 1996, pages 14082 - 14087
XIAO ET AL., J VIROL, vol. 70, 1996, pages 8098 - 8108
CHAO ET AL., MOL THER, vol. 2, 2000, pages 619 - 623
CHAO ET AL., MOL THER, vol. 4, 2001, pages 217 - 222
HERZOG ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 5804 - 5809
MURPHY ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 13921 - 13926
LEWIS ET AL., J VIROL, vol. 76, 2002, pages 8769 - 8775
MCPHERRON ET AL., NATURE, vol. 387, no. 6628, 1997, pages 83 - 90
MCPHERRON ET AL., NAT. GENET., vol. 22, no. 3, 1999, pages 260 - 264
HILL ET AL., J. BIOL. CHEM., vol. 277, no. 43, 2002, pages 40735 - 40741
HILL ET AL., MOL ENDOCRINOL, vol. 17, 2003, pages 1144 - 1154
ECKSTEIN, ANTISENSE NUCLEIC ACID DRUG DEV., vol. 10, 2000, pages 117 - 121
CROOKE, METHODS ENZYMOL., vol. 313, 2000, pages 3 - 45
GUVAKOVA ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 2620 - 2627
MANOHARAN, BIOCHIM. BIOPHYS. ACTA, vol. 1489, 1999, pages 117 - 130
BAKER ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 11994 - 12000
KURRECK, EUR. J. BIOCHEM., vol. 270, 2003, pages 1628 - 1644
SIERAKOWSKA; 1996 ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, pages 12840 - 12844
MARWICK, J. AM. MED. ASSOC., vol. 280, 1998, pages 871
TOMITA; MORISHITA, CURR. PHARM. DES., vol. 10, 2004, pages 797 - 803
GLEAVE; MONIA, NAT. REV. CANCER, vol. 5, 2005, pages 468 - 479
PATIL, AAPS J., vol. 7, 2005, pages E61 - E77
FRANCOIS ET AL., NUCLEIC ACIDS RES., vol. 16, 1988, pages 11431 - 11440
MOSER; DERVAN, SCIENCE, vol. 238, 1987, pages 645 - 650
KRUGER ET AL., TETRAHYMENA. CELL, vol. 31, 1982, pages 147 - 157
UHLENBECK, NATURE, vol. 328, 1987, pages 596 - 600
SIGURDSSON; ECKSTEIN, TRENDS BIOTECHNOL., vol. 13, 1995, pages 286 - 289
KUMAR ET AL., GENE THER., vol. 12, 2005, pages 1486 - 1493
BREAKER; JOYCE, CHEM. BIOL., vol. 1, 1994, pages 223 - 229
KHACHIGIAN, CURR. PHARM. BIOTECHNOL., vol. 5, 2004, pages 337 - 339
KHACHIGIAN, BIOCHEM. PHARMACOL., vol. 68, 2004, pages 1023 - 1025
TRULZSCH; WOOD, J. NEUROCHEM., vol. 88, 2004, pages 257 - 265
FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 811
MONTGOMERY ET AL., PROC. NATL. ACAD. SCI. US.A., vol. 95, 1998, pages 15502 - 15507
CULLEN, NAT. IMMUNOL., vol. 3, 2002, pages 597 - 599
HANNON, NATURE, vol. 418, 2002, pages 244 - 251
BERNSTEIN ET AL., NATURE, vol. 409, 2001, pages 363 - 366
NYKANEN ET AL., CELL, vol. 107, 2001, pages 309 - 321
GILMORE ET AL., J. DRUG TARGET., vol. 12, 2004, pages 315 - 340
REYNOLDS ET AL., NAT. BIOTECHNOL., vol. 22, 2004, pages 326 - 330
SOUTSCHEK ET AL., NATURE, vol. 432, 2004, pages 173 - 178
RALPH ET AL., NAT. MED., vol. 11, 2005, pages 429 - 433
XIA ET AL., NAT. MED., vol. 10, 2004, pages 816 - 820
MILLER ET AL., NUCLEIC ACIDS RES., vol. 32, 2004, pages 661 - 668
ELLINGTON; SZOSTAK, NATURE, vol. 346, 1990, pages 818 - 822
DOUDNA ET AL., PROE. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 2355 - 2359
TUERK; GOLD, SCIENCE, vol. 249, 1990, pages 505 - 510
WHITE ET AL., MOL. THER., vol. 4, 2001, pages 567 - 573
RUSCONI ET AL., NATURE, vol. 419, 2002, pages 90 - 94
NIMJEE ET AL., MOL. THER., vol. 14, 2006, pages 408 - 415
GRAGOUDAS ET AL., N. ENGL. J MED., vol. 351, 2004, pages 3805 - 2816
VINORES, CURR. OPIN. MOL. THER., 2003, pages 5673 - 679
KOURLAS; SCHILLER ET AL., CLIN. THER., vol. 28, 2006, pages 36 - 44
MORISHITA ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 5855 - 5859
ALEXANDER ET AL., J. AM. MED. ASSOC., vol. 294, 2005, pages 2446 - 2454
MANN; DZAU, J CLIN. INVEST., vol. 106, 2000, pages 1071 - 1075
NIMJEE ET AL., ANNU. REV. MED., vol. 56, 2005, pages 555 - 583
SRIVASTAVA ET AL., J. VIROL., vol. 45, 1983, pages 555 - 564
GAO ET AL., J. VIROL., vol. 78, 2004, pages 6381 - 63 88
MOL. THER., vol. 13, no. 1, 2006, pages 67 - 76
VIROLOGY, vol. 330, no. 2, 2004, pages 375 - 383
LAUGHLIN ET AL., GENE, vol. 23, 1983, pages 65 - 73
SENAPATHY; CARTER, J. BIOL. CHEM., vol. 259, 1984, pages 4661 - 4666
CARTER, CURRENT OPINIONS IN BIOTECHNOLOGY, 1992, pages 1533 - 539
MUZYCZKA, CURR. TOPICS IN MICROBIAL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129
RATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072
HERMONAT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6466
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251
MCLAUGHLIN ET AL., J. VIROL., vol. 62, 1988, pages 1963
LEBKOWSKI ET AL., MOL. CELL. BIOL., vol. 7, 1988, pages 349
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828
PERRIN ET AL., VACCINE, vol. 13, 1995, pages 1244 - 1250
PAUL ET AL., HUMAN GENE THERAPY, vol. 4, 1993, pages 609 - 615
CLARK ET AL., GENE THERAPY, vol. 3, 1996, pages 1124 - 1132
CLARK, HUM. GENE THER., vol. 10, no. 6, 1999, pages 1031 - 1039
SCHENPP; CLARK, METHODS MOL. MED, vol. 69, 2002, pages 427 - 443
WEINTRAUB ET AL., SCIENCE, vol. 251, 1991, pages 761 - 766
CSERJESI; OLSON, MOL CELL BIOL, vol. 11, 1991, pages 4854 - 4862
MUSCAT ET AL., MOL CELL BIOL, vol. 7, 1987, pages 4089 - 4099
JOHNSON ET AL., MOL CELL BIOL, vol. 9, 1989, pages 3393 - 3399
SEMENZA ET AL., PROC NATL ACAD SCI USA, vol. 88, 1991, pages 5680 - 5684
MADER; WHITE, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5603 - 5607
DUCLOS ET AL., J. CELL BIOL., vol. 142, no. 6, 1993, pages 1461 - 1471
KASPAR ET AL., MOL THER, vol. 5, 2002, pages 50 - 56
RABINOWITZ ET AL., J. VIROL., vol. 76, 2002, pages 791 - 801
GURNEY ET AL., SCIENCE, vol. 264, 1994, pages 1772 - 1775
XIAO; SAMULSKI, J VIROL., vol. 72, no. 3, 1998, pages 2224 - 2232
ABMAYR, MOL THER., vol. 12, 2005, pages 441 - 450

Citation (search report)

[I] US 2006251632 A1 20061109 - TREMBLAY JACQUES P [CA], et al
[Y] US 5786211 A 19980728 - JOHNSON PHILIP R [US]
[Y] US 2006094116 A1 20060504 - COLOSI PETER [US]
[YP] WO 2007053775 A1 20070510 - AMGEN INC [US], et al
[A] SNYDER R O ET AL: "Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice.", HUMAN GENE THERAPY 1 NOV 1997, vol. 8, no. 16, 1 November 1997 (1997-11-01), pages 1891 - 1900, XP002489591, ISSN: 1043-0342
[I] RIZO ET AL: "Recombinant AAV Gene Delivery of Follistatin for Muscle Enhancement in Models of Muscular Dystrophy", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 13, May 2006 (2006-05-01), pages S352, XP005676020, ISSN: 1525-0016
[A] WHITTEMORE L-A ET AL: "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 300, no. 4, 24 January 2003 (2003-01-24), pages 965 - 971, XP002281006, ISSN: 0006-291X
[AD] WAGNER K R: "MUSCLE REGENERATION THROUGH MYOSTATIN INHIBITION", CURRENT OPINION IN RHEUMATOLOGY, CURRENT SCIENCE, LONDON, GB, vol. 17, no. 6, 1 January 2005 (2005-01-01), pages 720 - 724, XP009077213, ISSN: 1040-8711
[Y] ROLLING F: "Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 11, no. Suppl. 1, 1 October 2004 (2004-10-01), pages S26 - S32, XP002528464, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302366
[Y] S. ZOLOTUKHIN: "Production of Recombinant Adeno-Associated Virus Vectors", HUMAN GENE THERAPY, vol. 16, no. 5, 1 May 2005 (2005-05-01), pages 551 - 557, XP055001693, ISSN: 1043-0342, DOI: 10.1089/hum.2005.16.551
[A] PATEL K: "Follistatin", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 30, no. 10, 1 October 1998 (1998-10-01), pages 1087 - 1093, XP009146327, ISSN: 1357-2725, DOI: 10.1016/S1357-2725(98)00064-8

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2008067480 A2 20080605; WO 2008067480 A3 20081030; CA 2693178 A1 20080605; CA 2693178 C 20181204; EP 2097095 A2 20090909; EP 2097095 B1 20160127; EP 2679237 A1 20140101; ES 2569365 T3 20160510; US 2010178348 A1 20100715; US 2015086636 A1 20150326; US 2017151348 A1 20170601; US 8895309 B2 20141125

DOCDB simple family (application)

US 2007085960 W 20071129; CA 2693178 A 20071129; EP 07864918 A 20071129; EP 13177677 A 20071129; ES 07864918 T 20071129; US 201414551834 A 20141124; US 201615208851 A 20160713; US 51699507 A 20071129